Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines (READY-4)
A Multicenter, Open-Label Study to Evaluate the Safety of QM1114-DP for the Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
Sponsor: Galderma R&D
This PHASE3 trial investigates Glabellar Lines and Lateral Canthal Lines and is currently completed. Galderma R&D leads this study, which shows 11 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Jul 2023 [monthly]
Completed PHASE3
-
Apr 2022 — Sep 2022 [monthly]
Completed PHASE3
▶ Show 6 earlier versions
-
Jun 2021 — Apr 2022 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2020 — Aug 2020 [monthly]
Recruiting PHASE3
-
Mar 2020 — Apr 2020 [monthly]
Recruiting PHASE3
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE3
First recorded
Jan 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Galderma R&D
For direct contact, visit the study record on ClinicalTrials.gov .